Comparison of Intravenous Injection of Calcium Antagonist and Beta-blockade on Endothelial Shear Stress of Coronary Artery
|ClinicalTrials.gov Identifier: NCT01171911|
Recruitment Status : Unknown
Verified April 2010 by Nanjing Medical University.
Recruitment status was: Not yet recruiting
First Posted : July 29, 2010
Last Update Posted : July 29, 2010
Both calcium channel antagonist and beta-blocker have cardioprotective effect. Endothelial shear stress is predictive factor of clinical outcomes in patients with obstructive stenosis.
The present study aims at comparing the re-distribution of shear stress and blood velocity during whole cardiac cycle after trans-coronary injection of Nicardipine and esmolol.
|Condition or disease||Intervention/treatment||Phase|
|Acute Coronary Syndrome Coronary Artery Disease||Drug: Nicardipine , Esmolol||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Nanjing First Hospital, Nanjing Medical University|
|Study Start Date :||October 2010|
|Estimated Primary Completion Date :||December 2010|
|Estimated Study Completion Date :||December 2010|
- Drug: Nicardipine , Esmolol
A loading dose of Nicardipine 10mg was at a bolus injected through vein , then continuous trans-venous titration at a speed 1ug/kg was kept. A loading dose of Esmolol 0.5mg/kg/min was at a bolus injected through vein , then continuous trans-venous titration at a speed 0.2mg/kg/min was kept.Other Name: Calcium channel blocker
- Endothelial shear stress assessed by computational fluid dynamics [ Time Frame: After four minutes ]At the peak effect of drug that the mean blood pressure (MBP) reduced by 10% or more, or the heart rate increased by 10-15 bpm.
- Minimal lumen area by intravascular ultrasound [ Time Frame: After four minutes ]At the peak effect of drug that the mean blood pressure (MBP) reduced by 10% or more, or the heart rate increased by 10-15 bpm.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01171911
|Contact: Shaoliang Chen, Directorfirstname.lastname@example.org|
|Nanjing First Hospital,Nanjing Medical University||Not yet recruiting|
|Nanjing, Jiangsu, China, 210006|
|Contact: Shao-liang Chen, Director +86-25-52208048 email@example.com|
|Study Chair:||Shao-liang Chen, Director||Nanjing First Hospital, Nanjing Medical University|